Free Chat Friday (Every Friday) -- Our live chat room with stock and option alerts! Fridays, starting at 9:30 am, go to: https://goo.gl/O3l5KC use the password: freechatfriday
Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Loading IDRA News...
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| AMGN | Amgen Inc. | -0.28% | 155.00 | 1.1% | $504.59m | |
| GILD | Gilead Sciences, Inc. | -0.40% | 64.30 | 0.9% | $489.93m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 0.00% | 455.70 | 2.7% | $466.21m | |
| CELG | Celgene Corporation | 0.00% | 116.74 | 1.1% | $419.11m | |
| BIIB | Biogen Inc. | -0.06% | 252.81 | 1.2% | $387.42m | |
| ALXN | Alexion Pharmaceuticals, Inc. | 0.86% | 99.35 | 1.9% | $353.97m | |
| INCY | Incyte Corporation | 0.00% | 138.41 | 2.6% | $272.84m | |
| VRTX | Vertex Pharmaceuticals Incorporated | 0.00% | 118.60 | 1.9% | $199.99m | |
| PBYI | Puma Biotechnology, Inc. | -1.60% | 76.80 | 21.1% | $199.46m | |
| ILMN | Illumina, Inc. | -0.02% | 173.72 | 3.5% | $195.96m | |
| EXAS | Exact Sciences Corporation | 0.00% | 33.19 | 28.0% | $151.08m | |
| A | Agilent Technologies, Inc. | 0.00% | 59.31 | 1.5% | $135.90m | |
| TSRO | TESARO, Inc. | 0.00% | 153.19 | 14.7% | $110.52m | |
| BMRN | BioMarin Pharmaceutical Inc. | 0.00% | 87.33 | 4.4% | $104.59m | |
| KITE | Kite Pharma, Inc. | 0.00% | 74.91 | 16.1% | $102.44m |
Company Profile
Idera Pharmaceuticals, Inc. is a clinical stage biotechnology company, which is engaged in discovery, development and commercialization of novel oligonucleotide therapeutics for oncology and rare diseases. The company uses two distinct proprietary drug discovery technology platforms to design and develop drug candidates: Toll-like receptor targeting technology and third-generation antisense technology. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Cambridge, MA.